Department of Biology, University of Rome "Tor Vergata", Rome, Italy; Italian Institute for Genomic Medicine (IIGM), Turin, Italy; Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy.
IRCSS - Regina Elena National Cancer Institute, Rome, Italy.
Cell Metab. 2019 Jul 2;30(1):36-50. doi: 10.1016/j.cmet.2019.06.001.
Tumor-associated macrophages (TAMs) constitute a plastic and heterogeneous cell population of the tumor microenvironment (TME) that can account for up to 50% of some solid neoplasms. Most often, TAMs support disease progression and resistance to therapy by providing malignant cells with trophic and nutritional support. However, TAMs can mediate antineoplastic effects, especially in response to pharmacological agents that boost their phagocytic and oxidative functions. Thus, TAMs and their impact on the overall metabolic profile of the TME have a major influence on tumor progression and resistance to therapy, de facto constituting promising targets for the development of novel anticancer agents. Here, we discuss the metabolic circuitries whereby TAMs condition the TME to support tumor growth and how such pathways can be therapeutically targeted.
肿瘤相关巨噬细胞（TAMs）构成肿瘤微环境（TME）中一种具有可塑性和异质性的细胞群体，在某些实体瘤中可占比高达 50%。TAMs 通常通过为恶性细胞提供营养支持来促进疾病进展和对治疗的耐药性。然而，TAMs 也可以介导抗肿瘤作用，特别是在增强其吞噬和氧化功能的药理制剂作用下。因此，TAMs 及其对 TME 整体代谢特征的影响对肿瘤进展和治疗耐药性有重大影响，事实上，TAMs 是开发新型抗癌药物的有前途的靶点。在这里，我们讨论了 TAMs 调节 TME 以支持肿瘤生长的代谢途径，以及如何对这些途径进行治疗性靶向。
